FDA
-
-
-
-
-
-
-
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
-
-
-
-
-
-
-
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
-
-
-
-
-
-
-
Mirum Pharmaceuticals completes enrollment in liver disease drug study
-
-
-
-
-
-
-
Mirum Pharmaceuticals receives Health Canada approval for LIVMARLI treatment
-
-
-
-
-
-
-
TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
-
-
-
-
-
-
-
Mirum presents liver disease drug data at AASLD conference
-
-
-
-
-
-
-
Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

